The legal action follows a sharp decline in Capricor’s market value after the U.S. Food and Drug Administration released briefing documents on July 27, 2026. These documents revealed that the company altered its statistical analysis plan without prior FDA review or agreement. Regulators determined these post-study changes were exploratory and lacked scientific justification, ultimately casting doubt on the effectiveness of Deramiocel.
Investors Face September Deadline in Capricor Therapeutics Lawsuit
Investors who lost more than $100,000 in Capricor Therapeutics securities between December 17, 2025, and July 26, 2026, have until September 28, 2026, to file as lead plaintiffs. The class action lawsuit, pending in the Southern District of California, alleges the company misled shareholders regarding its lead product candidate, Deramiocel.
Following the disclosure, Capricor’s stock plummeted 64%, closing at $7.00 per share. The lawsuit, Nkamga v. Capricor Therapeutics, Inc., et al., contends that executives failed to disclose material information in violation of federal securities laws. Investors seeking to participate or discuss their legal options may contact the firm Kahn Swick & Foti, LLC, which is overseeing the case.
Comments (0)
No comments yet. Be the first!